A5034897944- CAR-T cell therapy research
- Biosimilars and Bioanalytical Methods
- Biomedical Ethics and Regulation
- Glioma Diagnosis and Treatment
- Nerve injury and regeneration
- Neuroinflammation and Neurodegeneration Mechanisms
- Integrated Circuits and Semiconductor Failure Analysis
- Immunotherapy and Immune Responses
- Brain Metastases and Treatment
- Histiocytic Disorders and Treatments
- CNS Lymphoma Diagnosis and Treatment
- Multiple Sclerosis Research Studies
- SARS-CoV-2 and COVID-19 Research
- Blood groups and transfusion
- Stroke Rehabilitation and Recovery
- Signaling Pathways in Disease
- Immunodeficiency and Autoimmune Disorders
- Immune cells in cancer
- Peripheral Neuropathies and Disorders
- Viral Infectious Diseases and Gene Expression in Insects
- Neurogenesis and neuroplasticity mechanisms
- Nuclear Receptors and Signaling
- Ocular Diseases and Behçet’s Syndrome
- Cerebral Palsy and Movement Disorders
- Otitis Media and Relapsing Polychondritis
Stanford University
2022-2024
Stanford Medicine
2022-2024
Institute of Neuroimmunology of the Slovak Academy of Sciences
2024
Palo Alto University
2023
University of California, Los Angeles
2015-2016
Yale University
2010
Abstract Diffuse intrinsic pontine glioma (DIPG) and other H3K27M-mutated diffuse midline gliomas (DMGs) are universally lethal paediatric tumours of the central nervous system 1 . We have previously shown that disialoganglioside GD2 is highly expressed on cells demonstrated promising preclinical efficacy GD2-directed chimeric antigen receptor (CAR) T 2 , providing rationale for a first-in-human phase I clinical trial (NCT04196413). Because CAR cell-induced brainstem inflammation can result...
Synucleins are a vertebrate-specific family of abundant neuronal proteins. They comprise three closely related members, α-, β-, and γ-synuclein. α-Synuclein has been the focus intense attention since mutations in it were identified as cause for familial Parkinson's disease. Despite their disease relevance, normal physiological function synucleins remained elusive. To address this, we generated characterized αβγ-synuclein knockout mice, which lack all members this protein family. Deletion...
<p>Range and interquartile range of nadir serum electrolyte values in patients with without ICANS.</p>
<p>Neurological adverse events included within each neurological event category for CAR T-cell recipients.</p>
<p>Correlation between ICANS, CRS, and various electrolyte derangements with categories of neurological adverse events reported in CAR T-cell recipients.</p>
<p>Figure S3. ICANS incidence and time to symptom onset.</p>
<p>Figure S2. Trends in serum electrolyte concentrations following CAR T-cell infusion grouped by patient ICANS status.</p>
<p>Figure S7. Coincidence of serum hypocalcemia with hypophosphatemia.</p>
<p>Figure S5. Associations between pre-infusion tumor burden and ICANS hypophosphatemia.</p>
<p>Figure S4. Association of hypophosphatemia incidence by ICANS grade.</p>
<p>Figure S8. Baseline and change in kidney function following CAR T therapy grouped by patient ICANS status.</p>
<p>Stratification of CRS, ICANS, and hypophosphatemia incidence rates by pre-emptive treatment with tocilizumab.</p>
<p>Figure S1. Nadir serum electrolyte concentrations grouped by patient ICANS status.</p>
<p>Supplemental Figure Legends</p>
<p>Incidence of hypophosphatemia and AKI following CAR-T cell infusion.</p>
<p>Incidence of hypophosphatemia and ICANS in patients who developed CRS (n = 433).</p>
<p>Figure S6. Histogram plots of nadir phosphorus values stratified by ICANS status.</p>
CD19 chimeric antigen receptor (CAR) T-cell therapy has proven highly effective for treating relapsed/refractory mantle cell lymphoma (MCL). However, immune effector cell-associated neurotoxicity syndrome (ICANS) remains a significant concern. This study aimed to evaluate the clinical, radiological, and laboratory correlatives associated with ICANS development after CAR in patients MCL. All (N = 26) who received standard-of-care brexucabtagene autoleucel until July 2022 at our institution...
Immune effector cell-associated neurotoxicity syndrome (ICANS) is a prevalent condition seen after treatment with chimeric antigen receptor T-cell (CAR T) therapy and other cancer cell therapies. The underlying pathophysiology neuropathology of the clinical are incompletely understood due to limited availability brain tissue evaluation from patient cases, lack high-fidelity preclinical animal models for translational research. Here, we present cellular neuropathologic analysis who...
Abstract Brain metastases occur in 1% of sarcoma cases and are associated with a median overall survival 6 months. We report rare case brain metastasis unique radiologic histopathologic features patient low grade fibromyxoid (LGFMS) previously treated immune checkpoint inhibitor (ICI) therapy. The lone progressed the midbrain tegmentum over 15 months as non-enhancing, T2-hyperintense lesion peripheral diffusion restriction, mimicking demyelinating lesion. Histopathology at autopsy revealed...